New Weight Loss Drug Retatrutide Provides Double the Weight Loss of Ozempic, Lilly Says
Lilly said retatrutide produced greater weight loss and better blood sugar control than Ozempic, with similar side effects in a yearlong trial.
- On Wednesday, October 28, 2026, Eli Lilly and Company announced positive topline results from the TRANSCEND-T2D-2 Phase 3 trial, showing its experimental drug retatrutide outperformed Novo Nordisk's Ozempic in adults with type 2 diabetes.
- The investigational once-weekly drug activates three hormone receptors—GLP-1, GIP, and glucagon—earning it the nickname 'triple-G,' which Lilly believes could transform cardiometabolic care by combining appetite suppression with increased calorie burning.
- At 80 weeks, retatrutide lowered A1C by an average of 2.2% versus 1.8% for Ozempic, while patients on the highest dose lost an average of 47.4 pounds compared with 20.9 pounds on Ozempic.
- Most adverse events were mild-to-moderate, with treatment discontinuation rates due to side effects reaching 7.9% for the 12 mg retatrutide dose, compared to 2.7% for participants taking Ozempic 2 mg.
- While Eli Lilly intends to submit retatrutide for regulatory approval in early 2027, the company warned that the drug is currently investigational and cautioned against illegal, pre-approval sales of unauthorized 'reta' products.
18 Articles
18 Articles
Eli Lilly's new remedy Retatrutide causes patients to lose significantly more weight than Ozempic in one study. Although the product is still waiting for its approval, counterfeiting products are already flourishing on the black market.
New weight loss drug proves twice as powerful as Ozempic’s highest dosage
Eli Lilly’s experimental obesity and diabetes treatment helped patients lose more than twice as much weight as Ozempic’s highest approved dose in a head-to-head trial, while also improving blood sugar and other cardiovascular risk factors.
Eli Lilly's new generation drug for weight loss, the retatrutide, has largely surpassed Novo Nordisk's Ozempic, in a direct comparative study, informed Lilly on Wednesday (28). New's actions retreated after the announcement. Exclusive material for subscribers. To have full access, access the link of the subject and register.
Retatrutide beats Ozempic on weight loss, blood sugar control
Coverage Details
Bias Distribution
- 44% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
